Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalyst Pharm Inc
(NQ:
CPRX
)
19.95
-0.05 (-0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
August 16, 2023
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023
Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
August 15, 2023
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.
Via
Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
August 15, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
5 Analysts Have This to Say About Catalyst Pharmaceuticals
August 11, 2023
Via
Benzinga
Where Catalyst Pharmaceuticals Stands With Analysts
July 21, 2023
Via
Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
June 21, 2023
Via
Benzinga
Exelixis Stock Sees Rising Relative Strength Rating
August 14, 2023
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
August 14, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
August 03, 2023
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.
Via
InvestorPlace
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
July 25, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
July 24, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
July 19, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
July 02, 2023
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential.
Via
InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
June 28, 2023
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...
Via
Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
June 21, 2023
Via
Benzinga
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
June 20, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
The 7 Best Stocks Under $15 to Buy in June 2023
June 01, 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.
Via
InvestorPlace
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
June 01, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
May 30, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
May 22, 2023
When evaluating investments, it helps to keep quarterly performance in context.
Via
The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
May 15, 2023
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
Via
Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
May 12, 2023
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.
Via
Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
May 11, 2023
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
May 10, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 11, 2023
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Via
Benzinga
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
May 09, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
May 01, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.